Brian Orelli, PhD

The biotech has multiple drugs in preclinical development.

The biotech has taken a broad approach to development, but has it cost the company time?

The biotech's lead vaccine candidate is still being tested in animals.

The company is waiting for the FDA to authorize the start of a clinical trial testing the next-generation product.

Despite multiple treatments, vaccines, and tests for COVID-19 developed by leading competitors, Sorrento's CEO Henry Ji thinks the company still has an opportunity to thrive.

The company has two therapeutic antibodies in development.

The agency concluded there's no evidence that the drug improves survival or positively impacts other outcomes.

The company is developing tests in all three classes: antibody, molecular, and antigen tests.

The biotech's executives shrug off the potential for vaccines to reduce the market opportunity for its COVID-19 treatments.

The company's focus on antibodies helped it pivot into COVID-19.

It's a two-horse race -- for now.

The Oracle of Omaha and his team opened new positions in the underperforming sector.

The biotech posted clinical trial data that left more to be desired.

The company has begun shipment of the initial 300,000 doses.

Investors grow weary of the high-flying COVID-19 company.

The biotech stopped development of a midstage drug, but the company has a backup plan.

A solid third quarter plus an acquisition to drive future growth has investors giddy.

The committee of outside experts saw right through the FDA's cheerleading.

A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.

The day is finally upon us.